Editorial Expression of Concern Issued for Lixisenatide Neurogenesis Study

BMC Neuroscience published an Editorial Expression of Concern on October 29, 2026, concerning a study involving lixisenatide. The publication is titled "Editorial Expression of Concern: Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis." This notice pertains to the original article examining liraglutide and lixisenatide, both diabetes treatments, and their reported effects on crossing the blood brain barrier and enhancing neurogenesis. The item appears in BMC Neuroscience as an editorial action rather than a new research finding. No specific findings, data, or conclusions from the original study are detailed in this notice beyond its title and the fact that a concern has been raised. The event record does not specify the nature of the concern or any outcome of ongoing review. Readers should note that an Editorial Expression of Concern is a formal journal notice and does not itself confirm any issue with the compound's safety or efficacy. Lixisenatide remains an approved medication. Those interested in the broader context of this compound, including its approved uses and regulatory history, can consult the compound overview for additional background.